November 2009 PBAC Outcomes - Deferrals

PDF Printable Version of November 2009 PBAC Outcomes - Deferrals

DRUG AND FORM	DRUG USE AND TYPE	LISTING REQUESTED BY SPONSOR	PBAC OUTCOME AND COMMENT
Pemetrexed disodium, powder for IV infusion, 100 mg (base) and 500 mg (base), (Alimta^®) Eli Lilly Australia Pty Ltd Major submission	Anti-cancer drug	Extend the current Authority Required listing to include first-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) with predominantly non-squamous cell histology in combination with cisplatin.	The PBAC considered the incremental cost-effectiveness ratio to be high and uncertain, and deferred the submission to allow for further dialogue with the sponsor on several identified issues.
		Sponsor’s comments:	Eli Lilly will continue to work with the PBAC to clarify the issues outstanding and work towards an acceptable positive recommendation

DRUG AND FORM

DRUG USE AND TYPE

LISTING REQUESTED BY SPONSOR

PBAC OUTCOME AND COMMENT

Pemetrexed disodium, powder for IV infusion, 100 mg (base) and 500 mg (base), (Alimta^®)

Eli Lilly Australia Pty Ltd

Major submission

Anti-cancer drug

Extend the current Authority Required listing to include first-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) with predominantly non-squamous cell histology in combination with cisplatin.

The PBAC considered the incremental cost-effectiveness ratio to be high and uncertain, and deferred the submission to allow for further dialogue with the sponsor on several identified issues.

Sponsor’s comments:

Eli Lilly will continue to work with the PBAC to clarify the issues outstanding and work towards an acceptable positive recommendation

November 2009 PBAC Outcomes - Deferrals

Department of Health and Aged Care

Pharmaceutical Benefits Scheme

PBS Information

Browse the PBS

For Health Professionals

For Industry